(Reuters) – Gilead Sciences Inc (GILD.O) is developing easier-to-administer versions of its antiviral treatment remdesivir for COVID-19 that could be used outside of hospitals, including ones that can be inhaled, after trials showed moderate effectiveness for the drug given by infusion. Remdesivir is the only drug so far that has been shown to help patients with COVID-19, but Gilead and other companies are looking for ways to make it work better. For critically ill patients, Roche (ROG.S) and Eli Lilly and Co (LLY.N) are testing drugs in combination with remdesivir. Gilead is also seeking to treat the virus earlier. Other antivirals, like influenza pill Tamiflu, work best when given as early as possible after someone becomes infected.